Navigation Links
Tocagen Expands Clinical Development Team;

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Tocagen Inc. today announced Wayne Saville, M.D., has been named vice president, clinical development, and Mary Rose Keller has been named vice president, clinical operations.

"As we advance Toca 511 & Toca FC into late-stage registration studies, we are expanding our clinical team with individuals who have deep experience in drug development, regulatory approval, launch and commercialization activities," said Jamey Skillings, M.D., Chief Medical Officer of Tocagen. "Wayne and Mary Rose bring decades of valuable expertise in clinical development and medical affairs at a pivotal time for Tocagen."

Dr. Saville has more than a decade of experience in clinical development and medical affairs for cancer products. Prior to joining Tocagen, he headed medical affairs at Genoptix, an oncology diagnostics laboratory acquired by Novartis. Previous to that position he was a director of clinical research at Amgen, where he led late-stage development of a cancer drug as well as medical affairs for Prolia. Prior to this role, Dr. Saville was the director of oncology clinical research at Biogen Idec, leading clinical and medical affairs programs for Zevalin® and Rituxan®. Previous to this position, he was an associate professor at the University of California, San Diego, and trained in internal medicine at the University of Minnesota Medical Center. He was a medical oncology fellow at the National Cancer Institute and obtained his medical degree and bachelor's degree in medicine at Northwestern University. 

Ms. Keller has more than two decades of experience in drug development and clinical operations, and has worked with numerous research-focused organizations while at University of California, San Francisco's Cancer Research Institute, including the Brain Tumor Research Group, Children's Cancer Study Group and Radiation Therapy Oncology Group. Previously she was the vice president of clinical development and operations at a number of pharmaceutical companies including Prometheus Laboratories and Shire. Prior, she was the senior director of clinical operations at Agouron, leading activities for Viracept®. She subsequently led Agouron's oncology and ophthalmology programs through mergers with Warner-Lambert and Pfizer, ultimately becoming Pfizer's worldwide head development operations, global team leads and clinical trial recruitment services. Ms. Keller also previously worked at New Drug Services, where she participated in eight New Drug Applications. Ms. Keller obtained her bachelor's degree at the University of California, Davis.

About Tocagen Inc.
Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products for the selective treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511 & Toca FC, the company's lead investigational combination product, is being evaluated in three clinical trials in patients with recurrent high grade glioma, including glioblastoma (GBM). Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 please visit or using the identifier NCT01470794NCT01156584 or NCT01985256

SOURCE Tocagen Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
2. Six Presentations on Tocagens Toca 511 to be Given at the Society of Neuro-Oncology Annual Meeting
3. Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagens Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma
4. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
7. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. PRA Expands Operations in Europe
10. USANA Health Sciences Expands Award-Winning Research and Development Team
11. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
Post Your Comments:
(Date:11/27/2015)... PHILADELPHIA , Nov. 27, 2015  Lannett ... that it has completed the acquisition of Kremers ... pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. ... --> Lannett has acquired KU from UCB ... to certain adjustments, including a customary working capital ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
Breaking Medicine Technology:
(Date:11/28/2015)... PITTSBURGH, PA (PRWEB) , ... November 28, 2015 , ... ... Manalapan, N.J., has created the COUCH BUDDY. "I conceived of this design due to ... more comfort for couch users. It promotes relaxation and convenience, as well as increases ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... carried out by the University of Toronto and the University of British Columbia suggested ... hospitalizations for head injuries. The article explains that part of the reason for the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
Breaking Medicine News(10 mins):